Electroretinogram changes in a pediatric population with epilepsy: Is vigabatrin acting alone?

Journal of Child Neurology

Volumn 26, Issue 6, 2011, Pages 729-733

  McCoy, Bláthnaid ^a   Wright, Thomas ^a   Weiss, Shelly ^a   Go, Cristina ^a   Westall, Carol A ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

electroretinogram; infantile spasms; retina; toxicity; vigabatrin

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CORTICOTROPIN; LAMOTRIGINE; PHENOBARBITAL; PREDNISOLONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFECT; ELECTRORETINOGRAPHY; FOCAL EPILEPSY; HUMAN; INFANT; INFANTILE SPASM; MAJOR CLINICAL STUDY; MONOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINA DISEASE; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; ELECTRORETINOGRAPHY; EPILEPSY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; RETINAL DISEASES; VIGABATRIN;

EID: 79957627713     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073810390213     Document Type: Article

References (37)

1. French JA Vigabatrin. Epilepsia. 1999 ; 40 (Suppl 5). S11 - S16.
2. Ben-Menachem E. Vigabatrin. Epilepsia. 1995 ; 36 (Suppl 2). S95 - S104.
3. Mumford JP, Cannon DJ Vigabatrin. Epilepsia. 1994 ; 35 (Suppl 5). S25 - S28.
4. Ben-Menachem E., Persson LI, Scheter PJ, et al. The effect of different vigabatrin treatment regimes on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol. 1989 ; 27 (Suppl 1). 79S - 85S. (Pubitemid 19180367)
5. Petroff OAC, Rothman DL, Behar KL, Collins BA, Mattson RH Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology. 1996 ; 47: 1567-1571. (Pubitemid 26422556)
6. Sills G., Patsalos PN, Butler E., et al. Concentration related pharmacodynamic studies with vigabatrin and tiagabine in rat brain and eye [abstract]. Epilepsia. 1999 ; 40 (Suppl 2). 132.
7. Aicardi J., Mumford JP, Dumas C., Woods S. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia. 1996 ; 37: 638-642. (Pubitemid 26249996)
8. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol. 1989 ; 27 (Suppl 1). 43S - 45S. (Pubitemid 19180361)
9. Sussman NM, Weiss KI, Schroeder CE Vigabatrin: effect on in vivo and ex vivo magnetic resonance imaging of dog brains (Abstract). Epilepsia. 1991 ; 31 (Suppl 1). 13.
10. Dracopoulos A., Widjaja E., Raybaud C., Westall CA, Snead OC 3rd. Vigabatrin associated reversible MRI signal changes in patients with infantile spasms. Epilepsia. 2010 ; 51: 1297-1304.
11. Eke T., Talbot JF, Lawdon MC Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997 ; 31: 180-181. (Pubitemid 27037871)
12. Harding GF, Wild JM, Robertson KA, Rietbrock S., Martinez C. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology. 2000 ; 55: 347-352. (Pubitemid 30650073)
13. Ponjavic V., Anreasson S. Multifocal ERG and full field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol. 2001 ; 102: 63-72. (Pubitemid 32618795)
14. Izumi Y., Ishikawa W., Benz AM, et al. Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. Epilepsia. 2004 ; 45: 1043-1048. (Pubitemid 39238113)
15. Jammoul F., Wang Q., Nabbout R., et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol. 2009 ; 65: 98-107.
16. Stefan HJ, Bernati K., Knoor HL Visual field constriction and anti-epileptic drug treatment. Neurol Psychiatr Brain Res. 2000 ; 7: 185-190.
17. Besch DA, Kurtenbach E., Apfelstedt-Sylla B., et al. Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol. 2002 ; 104: 151-170.
18. Wild JM, Robson CR, Jones A., Cunliffe IA, Smith PE Detecting vigabatrin toxicity by imaging the retinal nerve fibre layer. Invest Ophthalmol Vis Sci. 2006 ; 47: 917-924. (Pubitemid 46768322)
19. Wild JM, Martinez C., Reinshagen G., Harding GF Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia. 1999 ; 40: 1784-1794.
20. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin. Neurology. 1999 ; 53: 2082-2087.
21. Nousiainen I., Mantyjarvi M., Kalviainen R. No reversion in vigabatrin associated visual field defects. Ophthalmology. 2001 ; 57: 1916-1917. (Pubitemid 33096710)
22. Fledelius HC Vigabatrin-associated visual field constriction in a longitudinal series: reversibility suggested after drug withdrawal. Acta Ophthalmol Scand. 2003 ; 81: 41-46.
23. Westall CA, Buncic JR, Donner EJ, et al. Understanding the Vigabatrin-related Visual Field Defect: Infants. Poster presented at annual meeting of AES 2007.
24. Kinirons P., Cavalleri GL, O'Rourke D., et al. Vigabatrin Retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia. 2006 ; 47: 311-317.
25. Wong IC, Mawer GE, Sander JW Severe persistent visual constriction associated with vigabatrin. Reaction may be dose dependent. BMJ. 1997 ; 314: 1693-1694.
26. Blackwell N., Hayllar J., Kelly G. Severe persistent visual costrication associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing [letter]. BMJ. 1997 ; 314: 1694.
27. Harding GF Severe persistent visual constriction associated with vigabatrin. Four possible explanations exist [letter]. BMJ. 1997 ; 314: 1694.
28. Kramer G., Scollo-Lavizzari G., Jallon P., et al. Vigabatrin-associated bilateral concentric visual field defects in four patients. Epilepsia. 1997 ; 38 (Suppl 8). 179.
29. Mackenzie R., Klistorner A. Severe persistent visual constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin [letter]. BMJ. 1998 ; 316: 232.
30. Kalviainen R., Nousiainen I., Mantyjarvi M., et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology. 1999 ; 53: 922-926. (Pubitemid 29442104)
31. Lawden MC, Eke T., Degg C., et al. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry. 1999 ; 67: 716-722.
32. Wild JM, Martinez C., Reinshagen G., Harding GF Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia. 1999 ; 40: 1784-1794.
33. Buncic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, Logan WJ Characteristic retinal atrophy with secondary ''inverse'' optic atrophy identifies vigabatrin toxicity in children. Ophthalmology. 2004 ; 111: 1935-1942. (Pubitemid 39311851)
34. Lawthom C., Smith PE, Wild JM Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity. Ophthalmology. 2009 ; 116: 565-571.
35. Rapp LM, Thum LA, Anderson RE Synergism between environmental lighting and taurine depletion in causing photoreceptor cell degeneration. Exp Eye Res. 1988 ; 46: 229-238. (Pubitemid 18096475)
36. El Idrissi A., Messing J., Scalia J., Tranker E. Prevention of epileptic seizures by taurine. Adv Exp Med Biol. 2003 ; 526: 515-525.
37. Gupta RC, Win T., Bittner S. Taurine analogues: a new class of therapeutics: retrospect and prospects. Curr Med Chem. 2005 ; 12: 2021-2039. (Pubitemid 41015179)